ID   ZR75B Ad24
AC   CVCL_ZZ27
DR   cancercelllines; CVCL_ZZ27
DR   Wikidata; Q102115156
RX   PubMed=8562478;
RX   PubMed=9815641;
CC   Population: Caucasian.
CC   Doubling time: 41.3 hours (PubMed=8562478; PubMed=9815641).
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_5614 ! ZR-75-B
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 05-10-23; Version: 7
//
RX   PubMed=8562478;
RA   Wosikowski K., Regis J.T., Robey R.W., Alvarez M., Buters J.T.M.,
RA   Gudas J.M., Bates S.E.;
RT   "Normal p53 status and function despite the development of drug
RT   resistance in human breast cancer cells.";
RL   Cell Growth Differ. 6:1395-1403(1995).
//
RX   PubMed=9815641;
RA   Wosikowski K., Schuurhuis D., Kops G.J.P.L., Saceda M., Bates S.E.;
RT   "Altered gene expression in drug-resistant human breast cancer
RT   cells.";
RL   Clin. Cancer Res. 3:2405-2414(1997).
//